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OBJECTIVE—Many guidelines recommend that patients with type 2 diabetes should aim to
reduce their intake of salt. However, the precise relationship between dietary salt intake and
mortality in patients with type 2 diabetes has not been previously explored.
RESEARCH DESIGN AND METHODS—Six hundred and thirty-eight patients
attending a single diabetes clinic were followed in a prospective cohort study. Baseline sodium
excretion was estimated from 24-h urinary collections (24hUNa). The predictors of all-cause and
cardiovascular mortality were determined by Cox regression and competing risk modeling, re-
spectively.
RESULTS—The mean baseline 24hUNa was 184 6 73 mmol/24 h, which remained consistent
throughout the follow-up (intraindividual coefﬁcient of variation [CV] 23 6 11%). Over a
median of 9.9 years, therewere175 deaths,75 (43%) of whichweresecondary to cardiovascular
events. All-cause mortality was inversely associated with 24hUNa, after adjusting for other base-
line risk factors (P , 0.001). For every 100 mmol rise in 24hUNa, all-cause mortality was 28%
lower (95% CI 6–45%, P = 0.02). After adjusting for the competing risk of noncardiovascular
death and other predictors, 24hUNa was also signiﬁcantly associated with cardiovascular mor-
tality (sub-hazard ratio 0.65 [95% CI 0.44–0.95]; P = 0.03).
CONCLUSIONS—Inpatientswithtype2diabetes,lower24-hurinarysodiumexcretionwas
paradoxically associated with increased all-cause and cardiovascular mortality. Interventional
studies are necessary to determine if dietary salt has a causative role in determining adverse
outcomes in patients with type 2 diabetes and the appropriateness of guidelines advocating salt
restriction in this setting.
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I
n patients with type 2 diabetes, hyper-
tension is associated with a range of
adverseoutcomesincludingcardiovas-
cular disease (CVD) and premature mor-
tality. Consequently, clinical guidelines
recommend that patients with type 2
diabetes undertake measures to main-
tain a blood pressure at or below target
levels. Among the interventions advo-
cated to assist in achieving these targets,
most guidelines recommend a reduced
intake of salt, as dietary sodium intake is
positively correlated with blood pressure
levels in the general population (1).
Moreover, in patients with type 2 diabe-
tes, salt restriction confers a modest re-
duction in blood pressure (2), and salt
supplementationreducestheantihyperten-
sive efﬁcacy of blood pressure–lowering
agents in the short term (3). However,
the precise relationship between salt in-
take and mortality in patients with type 2
diabetes has not been previously ex-
plored. It is widely assumed that any
blood pressure lowering associated with
reduced dietary salt intake may be trans-
lated into protection from end-organ
damage in the context of diabetes.
However, there is also evidence that re-
duced sodium intake is associated with ac-
tivation of metabolic and neurohormonal
pathways, including the sympathetic ner-
voussystem(4) and the renin-angiotensin-
aldosterone system (RAAS) (4), as well as
increases in total and LDL cholesterol (4)
and reduced peripheral insulin sensitivity
(5). In the context of type 2 diabetes, each
of these factors may offset or even out-
weighgainsachievedfrombloodpressure
lowering. Hence, in this study we ex-
plored the association between dietary
salt intake, the best estimate of which is
24-h urine collection as ;90% of dietary
sodium intake is renally excreted (6), and
all-cause and cardiovascular mortality in
patients with type 2 diabetes.
RESEARCH DESIGN AND
METHODS
Patient recruitment
This study was initiated in July 2000 as a
prospectivesurveyof patientswith type 2
diabeteswhowereinlong-termfollow-up
inasinglediabetesclinicatAustinHealth,
Melbourne, Australia. Austin Health is a
major university teaching hospital and a
tertiary referral center, serving a popu-
lation of approximately 700,000. Long-
termfollow-up was deﬁned bythe patients
having at least three previous estimations
of urinary albumin excretion rate (AER)
performed on 24-h urine collections with
at least one AER having been performed
within the year 2000. Patients with type 1
diabetes or diabetes secondary to medica-
tion or pancreatitis were speciﬁcally ex-
cluded fromthe currentstudy.Using these
criteria, 665 patients with type 2 diabetes
were eligible to participate in the survey.
Informed consent was obtained from par-
ticipatingpatientsasapprovedbytheAustin
Health Human Research Ethics Committee.
Measurement of baseline
characteristics
Baseline data collection was performed
during routine clinical visits between
JanuaryandDecember2001.Baselineclin-
ical and biochemical characteristics of all
participants were ascertained including a
full clinical history, medication use, an-
thropometric data, and smoking habits.
The presence of preexisting CVD was
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Pathophysiology/Complications
ORIGINAL ARTICLEdeﬁned on the basis of a clinical history of
myocardial infarction, unstable angina re-
quiring hospitalization, coronary revascu-
larization (including coronary artery
bypass grafting, angioplasty, or coronary
stenting), heart failure, stroke, carotid
artery surgery, peripheral revasculariza-
tion (including bypass grafting, angio-
plasty, or stenting), and amputation for
critical limb ischemia. Fasting blood sam-
ples were taken for glucose, HbA1c, lipid
proﬁles, and creatinine. The glomerular
ﬁltration rate was estimated (eGFR) using
the chronic kidney disease-epidemiology
collaboration (CKD-EPI) formula.
All regularly attending patients at the
Austin Health diabetes clinics perform a
24-h urine collection before each visit for
the determination of urinary sodium,
potassium, and albumin excretion using
standard methods in the Department of
Laboratory Medicine at Austin Health.
Baseline levels for each participant were
determined as the mean excretion rates
acrossallurinesamplesperformedduring
2001. Data on 24hUNa were available in
638 participants (96%) who formed the
study cohort (Supplementary Figure 1).
The clinical characteristics of these pa-
tients were not different from those in
whom 24hUNa was not measured.
Patients were given general dietary
advice as part of their routine care at an
initial assessment by a dietitian. However
detailed assessment of dietary salt intake
was not performed. During follow-up, all
patients continued to have standard med-
ical care including antihypertensive, lipid-
lowering, and antidiabetic medications
according to recommended guidelines.
Mortality outcomes
Theprimaryoutcomewasdeathfromany
cause until the 31 March 2010. Timing
and cause of death were identiﬁed from a
search of hospital patients’ records and
the Australian Institute of Health and
Welfare Death Registry. To evaluate the
independent predictors of all-cause mor-
tality in patients with type 2 diabetes, we
used Cox proportional hazards models.
The ﬁnal model variables were deter-
mined by sequential penalized likelihood
(Akaike information criterion) (7). The
functional form (in particular, nonlinear-
ity) of continuous variables in the ﬁnal
model was explored by both fractional
polynomials and restricted cubic splines
(7).Categoricalvariableswereparameter-
ized as simple indicator variables; the po-
tential for multicollinearity was assessed
using the variance inﬂation factor and
condition number. Overall Cox model
ﬁt was assessed by approximation of
cumulative Cox-Snell residuals to (-log)
Kaplan-Meier estimates, residual plots,
and testing of the proportional hazards
assumption and goodness-of-ﬁtt e s t( 8 ) .
The cumulative hazard of all-cause mor-
tality was graphically displayed using
Nelson-Aalen estimates stratiﬁed by per-
centiles of covariate(s) of interest (9).
Table 1—Baseline characteristics of patients with type 2 diabetes, stratiﬁed according to tertiles (T) of 24-h urinary sodium excretion
Baseline parameter
T1 T2 T3
,150 mmol/24 h 150–208 mmol/24 h .208 mmol/24 h
Age (years) 67 6 12* 64 6 11 61 6 12*
Sex (% male) 42* 56 70*
Diabetes duration (years) 14 6 9* 12 6 81 1 6 8
Obese (BMI .30 kg/m
2) (%) 41 45 55*
Macrovascular disease (%) 49 43 44
Coronary heart disease (%) 34 32 37
Atrial ﬁbrillation (%) 20 20 12*
Congestive cardiac failure (%) 17 11 15
C-reactive protein (geometric mean; IU/mL) 2.4 2.1 2.6
Systolic blood pressure (mmHg) 141 6 17 140 6 17 140 6 16
Diastolic blood pressure (mmHg) 77 6 10* 80 6 97 8 6 10*
Antihypertensive therapy (%) 78 78 76
ACE inhibitor (%) 45* 56 57
Angiotensin receptor blocker (%) 13 13 10
Diuretic (%) 38 32 42
b-Blocker (%) 23* 15 20
Calcium channel blocker (%) 34 28 34
a-Blocker (%) 5 5 5
HbA1c (%) 7.8 6 1.7 7.8 6 1.3 7.7 6 1.5
Fasting plasma glucose (mmol/L) 9.6 6 4.0 9.3 6 3.2 9.3 6 3.7
Metformin (%) 50 57 58
Sulfonylurea (%) 37* 51 40*
Insulin (%) 49%* 36% 39%
LDL cholesterol (mmol/L) 2.6 6 0.8 2.7 6 0.8 2.6 6 0.8
Triglycerides (mmol/L) 2.0 6 1.8 2.0 6 1.4 2.2 6 1.6
HDL cholesterol (mmol/L) 1.2 6 0.4 1.2 6 0.3 1.1 6 0.3
S t a t i n ( % ) 5 35 24 9
eGFR (mL/min/1.73 m
2)6 7 6 26* 73 6 25 78 6 24*
Albuminuria (micro and macro, %) 42 42 50
Hemoglobin (g/dL) 13.2 6 1.5 13.4 6 1.5 13.7 6 1.5*
Data are mean 6 SD unless otherwise indicated. *P , 0.01 vs. middle tertile (T2).
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Salt and mortality in type 2 diabetesTo identify the independent predic-
tors of the cumulative incidence of car-
diovascular mortality, we used the Fine
and Gray model, which extends the Cox
proportionalhazardsmodeltocompeting
risks data (10) by considering the subdis-
tribution hazard while adjusting for the
competing risk of noncardiovascular
deaths.Thestrengthoftheassociationbe-
tween each variable and the outcome was
assessed using the sub-hazard ratio,
which is the ratio of hazards associated
with the cumulative incidence function
inthe presence andabsence of a prognos-
tic factor. The Fine and Gray model was
implemented in Stata statistical software
( V 1 1 ,2 0 0 9 ;C o l l e g eS t a t i o n ,T X )u s i n g
the stcrreg module.
RESULTS
Cohort characteristics
The mean age of participants was 64
years, 56% were men, the median dura-
tion of diabetes was 11 years, and 47%
were obese (BMI .30 kg/m
2). Complica-
tions of diabetes were common with
45% of participants having previously
experienced a cardiovascular event, in-
cluding 35% who had a myocardial in-
farction. One-third had background
retinopathy on ophthalmological review
(33%), 30% had an eGFR ,60 mL/min/
1.73 m
2, and 45% had elevated urinary
albuminexcretion(.20mg/min),includ-
ing 13% with macroalbuminuria (.200
mg/min). Eighty-ﬁve percent of patients
had hypertension (deﬁned by the use
of antihypertensives and/or blood pres-
sure .140/90). Achievement of thera-
peutic targets was low, reﬂecting the
tertiary referral nature of the clinic,
with two-thirds of patients having an
HbA1c.7.0%,55%withanLDLcholes-
terol level .2.5 mM, and 44% with a
systolic blood pressure .140 mmHg.
24-h urinary sodium excretion
Baseline urinary sodium excretion was
estimated in 638 patients from a median
of two collections performed during the
year 2001 (range 1–5). The mean urinary
sodium excretion was 184 mmol/24 h,
similar to previous global population sur-
veys (11). One-third of participants had a
sodium excretion,150mmol/24h(low-
esttertile),andone-thirdhadanexcretion
.208 mmol/24 h (highest tertile) with
the middle tertile falling between 150
and208mmol/24h.Patientswithurinary
sodium excretion in the highest tertile
were younger, with a shorter duration of
diabetes,morelikelytobeobese,butwith
better renal function, and hemoglobin,
when compared with patients in tertile 2
(Table 1). Sex was also a strong predictor
of sodium excretion, consistent with the
higher sodium intake described in men
in global population surveys (11). On
multivariate analysis, 24hUNa (as a con-
tinuous variable) was positively corre-
lated with eGFR, BMI, male sex, and the
use of ACE inhibitors and was negatively
correlated with age (full regression model
[Supplementary Table 1]). The presence
Figure 1—Cumulative hazard (Nelson-Aalen) of all-cause mortality, stratiﬁed by percentiles (5th, 25th, 75th, and 95th) of 24-h urinary sodium
excretion. All-cause mortality was inversely associated with 24-h urinary sodium excretion.
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Ekinci and Associatesorabsenceofheartfailure,atrialﬁbrillation,
and the use of diuretics or b-blockers was
not associated with 24hUNa after adjusting
for age and sex.
Variability in sodium excretion
Baseline 24hUNa excretion was strongly
correlated with the yearly mean 24hUNa
during follow-up. Over two-thirds of
individuals with 24hUNa in the highest
tertile at baseline remained in the highest
tertileinsubsequentyears.Similarly,over
two-thirds of individuals with 24hUNa in
the lowest tertile remained in the lowest
tertile in subsequent years (data not
shown). Less than 5% of individuals
changed from the lowest to the highest
tertile or the highest to the lowest tertile
on an annual basis. Overall, the intrain-
dividual CV of mean annual 24hUNa was
23 6 11% over 8 years.
Mortality and 24-h urinary sodium
excretion
Vital status was determined in 620 pa-
tients with the remaining 18 (3%) lost to
follow-up. The median follow-up for
survival analysis was 9.9 years (5,475
patient-years) during which 175 deaths
were recorded (28%).CVD was listed as a
major contributing cause in 75 deaths
(43% of all deaths) with the other major
causes of death including cancer (n = 36)
and infection (n = 19). In 17 patients, al-
though death was veriﬁed, no cause of
death could be ascertained.
All-cause mortality was inversely as-
sociated with 24hUNa such that individu-
als with the lowest 24hUNa had the
highest cumulative hazard for mortality
(Fig.1).After adjustingforparameters as-
sociated with 24hUNa,a sw e l la so t h e r
factors independently associated with
all-cause mortality (including age, sex,
duration of diabetes, atrial ﬁbrillation,
the presence and severity of CKD (eGFR
and log AER) for every 100 mmol rise in
24hUNa, all-cause mortality was 28%
lower (95% CI 6–45%, P = 0.02) (Table 2).
Overall, 24hUNa explained 7% of the var-
iability (R
2 = 0.07, 95% CI 0.02–0.14)
in all-cause mortality in this cohort. No
signiﬁcant interactions between categorical
variables or between categorical and con-
tinuousvariablesweredemonstratedinthe
model implying the relative hazard associ-
ated with sodium intake was uniform re-
gardless of the presence and severity of
hypertension, CVD, CKD, and other risk
factors. Moreover, its effect was stronger
thanforotherreversibleriskfactorsinclud-
ing LDL cholesterol and HbA1c, and was
equivalenttothatofsystolicbloodpressure
(Table 2). Interestingly, blood pressure
levels were inversely correlated with all-
cause mortality with no convincing evi-
dence of nonlinear effects including
J-curve associations.
Cardiovascular mortality was also
signiﬁcantly associated with 24hUNa
(Fig. 2) after adjusting for the compet-
ing risk of noncardiovascular death and
other predictors (Table 2). No association
was observed between 24hUNa and non-
cardiac deaths (data not shown). When
modeled as a continuous variable, the as-
sociation between 24hUNa and all-cause
and cardiovascular mortality was linear.
No convincing evidence of nonlinear ef-
fects, including J-shaped associations,
was demonstrated as judged by residual-
by-time analysis, fractional polynomials,
and (cubic) regression splines (7). Again,
no signiﬁcant interactions between cate-
gorical variables or between categorical and
continuous variables were demonstrated,
implying the relationship between 24hUNa
andmortalitywasindependentofBMI,age,
sex, and the type of antihypertensive ther-
apyorachievedlevelofbloodpressurecon-
trol. Furthermore, the association between
24hUNa and mortality was independent of
24-hpotassiumexcretion(datanotshown).
CONCLUSIONS—Advice to reduce
dietary salt intake is a key element of
many lifestyle intervention programs for
type 2 diabetes. However, the association
between dietary salt intake and mortality
outcomeshasnotbeenpreviouslystudied
speciﬁcally in the context of type 2 di-
abetes. In this article, we show that
24hUNa was independently associated
with all-cause and cardiovascular mortal-
ity in patients with type 2 diabetes such
that the highest mortality risks were ob-
served in individuals with the lowest so-
dium intake and vice versa.
Although such data may seem con-
trary to established dogma, in fact pre-
vious observational studies, both in the
general population and in hypertensive
patients, have failed to give consistent
results regarding the association of salt
Table 2—Independent associations with all-cause mortality and cumulative incidence of
cardiovascular mortality in individuals with type 2 diabetes
All-cause mortality
Baseline parameter Hazard ratio P 95% CI
24-h urinary sodium excretion
(per 100 mmol/day) 0.72 0.017 0.55–0.94
Age (per decade) 1.05 ,0.001 1.03–1.07
Male sex (yes/no) 1.51 0.013 1.09–2.09
Pre-existing CVD (yes/no) 1.85 0.001 1.30–2.64
eGFR (per 10 mL/min/1.73 m
2) 0.988 0.002 0.980–0.996
Atrial ﬁbrillation (yes/no) 1.97 ,0.001 1.39–2.81
Log10 AER 1.71 ,0.001 1.38–2.12
Systolic blood pressure (mmHg) 0.986 0.015 0.974–0.997
Diabetes duration (decades) 1.02 0.010 1.01–1.04
Cardiovascular mortality
Baseline parameter Sub-hazard ratio P 95% CI
24-h urinary sodium excretion
(per 100 mmol/day) 0.65 0.026 0.44–0.95
Male sex (yes/no) 1.93 0.011 1.17–3.20
Pre-existing CVD (yes/no) 1.88 0.014 1.14–3.11
eGFR (per 10 mL/min/1.73 m
2) 0.985 0.001 0.98–0.99
Atrial ﬁbrillation (yes/no) 2.78 ,0.001 1.71–4.53
Log10 AER 1.76 ,0.001 1.28–2.42
Systolic blood pressure (mmHg) 0.97 ,0.001 0.96–0.99
Diabetes duration (decades) 1.05 ,0.001 1.02–1.08
All-cause mortality: independent associations with all-cause mortality in individuals with type 2 diabetes in
a multivariate Cox model. The model explained 52% of the variation in all-cause mortality (95% CI 0.42–
0.64) and was well speciﬁed (Harrell’s C: 0.79; PH test: P = 0.136; goodness-of-ﬁtt e s t :P $ 0.37). PH,
proportional hazard. Cardiovascular mortality: independent associations with the cumulative incidence of
cardiovascular mortality in individuals with type 2 diabetes in the Fine and Gray (proportional hazards)
model after accounting for the competing risk of noncardiovascular death.
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Salt and mortality in type 2 diabetesandmortality.Insomestudies,highersalt
intake has been associated with an in-
creased risk of cardiovascular events (12–
15), while in others—including the
National Health and Nutrition Examina-
tion Surveys (NHANES) I, II, and III—
lower salt intake has been associated
with an increased risk of cardiovascular
events and or mortality (16,17). Other
studies in the general community have
failed to demonstrate any association of di-
etary salt intake with cardiovascular events
(18–20). Although hypertension and CVD
are common in patients with type 2 diabe-
tes, the issue of whether dietary salt intake
inﬂuences mortality and morbidity has not
been studied speciﬁcally in the context of
type 2 diabetes, and any inference from
outcomes in other populations should be
viewed with caution.
The major strength of the current
study is the use of multiple 24-h urine
collections to estimate dietary sodium
intake. With few exceptions (13,16), the
majority of previous studies that have ex-
amined the association between salt and
mortality, including NHANES (17), have
relied on dietary recall, which can under-
estimate dietary salt intake by up to half
(21). All patients were trained in urine
collection and were experienced in per-
forming 24-h urine collections at the start
of the study. Moreover, in this popula-
tion, the annual intraindividual CV of
24hUNa was low (23% over an 8-year pe-
riod). In addition, the urinary sodium ex-
cretion observed was very similar to
previous global population surveys (11),
conﬁrming that the patients were not
sodium-restricted, which may otherwise
confound analysis by indication.
The chief limitations of our data are
that they are context-speciﬁc. The ﬁnd-
ings of our study speciﬁcally detail out-
comes in a high-risk subpopulation of
patients with longstanding type 2 diabetes
attending a tertiary referral center. None-
theless, these are precisely the patients
in whom more aggressive lifestyle inter-
ventions are often applied. Our patients
were mostly obese, hypertensive, with a
history of poor metabolic control, and
multiple comorbidities, including a sig-
niﬁcant burden of renal impairment and
preexisting CVD at baseline. In all pa-
tients, cardiac risk factors were treated
aggressively. It is possible that in this
clinical setting, nontraditional risk factors
have a stronger relationship with out-
comes or that paradoxical associations are
observed (22). For example, most of our
patients were hypertensive despite treat-
ment, and it has been previously shown
in treated hypertensive men that low
24hUNa is associated with an increased
risk of cardiovascular morbidity and mor-
tality (16) and that tight blood pressure
control in diabetic patients is associated
with increased all-cause mortality (23).
Figure 2—The cumulative incidence (Fine and Gray)ofcardiovascularmortality over the5th, 25th, 75th,and 95th percentile (A–D,respectively)
of 24-h urinary sodium excretion in men and women (solid line and dotted line, respectively), adjusted for other covariate predictors (Table 2) and
accounting for noncardiovascular mortality as the competing risk. The other predictors are set at: eGFR = 76.6 mL/min/1.73 m
2 (median); atrial
ﬁbrillation = yes; preexisting cardiovascular disease = yes; Log10 AER = 1.2 (median); systolic blood pressure = 140 mmHg (mean); diabetes
duration = 10.4 years (median).
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Ekinci and AssociatesHowever, in our study, the relationship
between urinary sodium excretion and
mortalitywasindependentofthepresence
and severity of hypertension.
In our statistical analysis, we speciﬁ-
cally assessed the nonlinear effects of
predictive variables modeled for potential
interactions and, in the case of cardiovas-
cular mortality, modeled within the par-
adigm of a formal competing risks (Fine
and Gray) model, which estimated the
cumulative incidence of cardiovascular
deaths while taking into consideration
the competing risk of other causes of
death, which may otherwise confound
results (24).Thisstrategyisespecially im-
portant in patients with diabetes, as dia-
betes is also associated with increased
noncardiovascular mortality (25), which
may potentially confound cause-speciﬁc
analysis. Although such strategies have a
number of advantages, it is nevertheless
possible that associations demonstrated
inthisstudymaybebecauseofconfound-
ing by unmeasured factors or those that
are difﬁcult to quantify. Variability in di-
etary sodium intake may be associated
with a range of differences in diet compo-
sition, processing, and preparation that
may themselves impact on adverse out-
comes in diabetic individuals. For exam-
ple, sodium intake is dominated by
sodium added in manufactured foods in
Western diets, (;75% of intake) (11). In
addition, we cannot exclude the possibil-
ity that salt appetite and cardiovascular
risk are linked to a common unidentiﬁed
etiological factor.
Any pathophysiological mechanisms
that may underlie our observed associa-
tion between mortality and salt intake in
patients with type2 diabetes remainto be
established. Certainly, RAAS activity (4),
insulin resistance (5), catecholamine
levels (4), and lipids (4) may be inﬂu-
encedbysodiumintake,andeachofthese
potential mediators may be of particular
relevance in the setting of type 2 diabetes
and/or established atherosclerosis. For
example, dietary sodium restriction leads
to increased levels of angiotensin II and
aldosterone, chieﬂy via an increase in
plasma renin activity. Given the primacy
of RAAS in the development and progres-
sionofdiabetescomplications,asadjudged
by the efﬁcacy of RAAS blockade, it is per-
hapsnotsurprisingthatactivationofRAAS
by reducing sodium intake may also be as-
sociated with adverse outcomes. The same
may also be said for increased sympathetic
activity,insulinresistance,anddyslipidemia
associated with sodium restriction.
In summary, we show that 24hUNa,
the best marker of dietary sodium intake,
was negatively associated with all-cause
mortality speciﬁcally in the setting of
type 2 diabetes, after adjusting for base-
line risk factors. This may reﬂect the spe-
cialstatus ofdietarysaltandthepathways
it regulates in diabetic pathophysiology.
Such data call into question universal rec-
ommendations that all adults should en-
deavor to reduce their salt intake (12).
Ultimately, the explanation for our ﬁnd-
ings needs to be tested experimentally in
clinical trials performed speciﬁcally in di-
abetic patients.
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